In order to analyze the effects of commercially available insulin sensitizers on AD, researchers have used them to restore glucose metabolism in the brain of AD mouse models and demonstrated that these drugs are effective in overcoming AD symptoms by attenuating neuroinflammation and tau hyperphosphorylation (Yu et al., 2015). Here, MAPT is linked to Alzheimer disease.